Here's Why You Should Add HAE Stock to Your Portfolio Now

Haemonetics Corporation’s (HAE) growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the Plasma franchise. The robust uptake of the NexSys PCS system bodes well for its long-term growth. Strong financial stability also buoys optimism. Meanwhile, headwinds from fierce competition pose concerns for Haemonetics’ operations.In the past year, this Zacks Rank #2 (Buy) company’s shares have lost 12.3% against the industry’s 11.2% growth and the S&P 500 composite’s 25.7% rise.The ...